论文部分内容阅读
目的在体外培养树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK),联合回输给HBeAg阳性慢性乙型肝炎患者,观察其调节性T淋巴细胞(Treg细胞)的变化,探讨其临床意义。方法选取HBeAg阳性慢性乙型肝炎患者18例,从外周血中分离单核细胞,在体外诱导自体DC细胞和CIK细胞共培养,HBsAg负载,制备DC-CIK细胞,回输给患者,每周1次,共5次;治疗前及治疗后4周检测Treg细胞、肝功能ALT、乙肝病毒指标HBsAg、HBeAg、HBV DNA。结果治疗后4周18例患者Treg细胞比率下降,但无统计学意义,ALT治疗后(46.62±6.79)IU/L低于治疗前(112.28±23.09)IU/L(P<0.05)。18例中11例Treg细胞比率下降患者,HBsAg下降10例,HBeAg下降9例,HBV DNA下降8例。结论 DC-CIK联合治疗能下调Treg细胞比率,发挥了免疫调节作用,起到了保肝降酶及抗病毒的作用。
Objective To culture dendritic cells-cytokine-induced killer cells (DC-CIK) in vitro and combine them with HBeAg-positive chronic hepatitis B patients to observe the changes of regulatory T lymphocytes (Treg cells) significance. Methods 18 cases of HBeAg-positive chronic hepatitis B patients were selected from the peripheral blood mononuclear cells, in vitro induction of autologous DC cells and CIK cells co-culture, HBsAg load, DC-CIK cells were prepared and returned to patients every week 1 Times, a total of 5 times; before treatment and 4 weeks after treatment Treg cells, liver function ALT, hepatitis B virus markers HBsAg, HBeAg, HBV DNA. Results The percentage of Treg cells in 18 cases decreased 4 weeks after treatment, but the IU / L was lower than that before treatment (112.28 ± 23.09 IU / L, P <0.05) after ALT treatment (46.62 ± 6.79). Of the 18 patients, the percentage of Treg cells was decreased in 11 patients. There were 10 cases with decreased HBsAg, 9 cases with decreased HBeAg and 8 cases with decreased HBV DNA. Conclusions DC-CIK combination therapy can down-regulate Treg cell ratio and exert immunomodulatory effects, which play a role in protecting liver and reducing blood enzymes and antivirus.